Abstract
The results of a recent phase 2 trial have shown that combined treatment with neratinib and capecitabine is active in patients with refractory HER2-positive breast cancer who have brain metastases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
